Status:
COMPLETED
Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV
Lead Sponsor:
Azienda Sanitaria Locale di Matera
Conditions:
Benign Paroxysmal Positional Vertigo (BPPV)
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Randomized, 3-arm controlled clinical study, to evaluate the effectiveness of supplementation with Vertistop® D (food supplement containing alpha-lipoic acid at modified release, Carnosine and Zinc, V...
Detailed Description
Benign paroxysmal positional vertigo (BPPV) is the most common type of vertigo detectable in otoneurological clinical practice. It is characterized by violent, short and relapsing vertiginous crises t...
Eligibility Criteria
Inclusion
- Diagnosis of primary BPPV;
- Patients having BPPV of CSP or CSL (geo or apo, single or multi channel);
- Patients with recurrent BPPV, defined as two or more episodes over the last six months, or three or more episodes in the last 12 months;
- Informed consent.
Exclusion
- Patients under 18 years of age;
- Secondary BPPV;
- Vitamin D levels greater than 100 ng/mL (\>250 nmol/L);
- Pregnant or breastfeeding.
Key Trial Info
Start Date :
December 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 3 2020
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04849182
Start Date
December 4 2018
End Date
November 3 2020
Last Update
April 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Policoro Hospital "Giovanni Paolo II"
Matera, Italy, 75100